The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
|
|
|
- Coleen Nash
- 5 years ago
- Views:
Transcription
1 The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018
2 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and regimens that are currently available Issues that affect the aging HIV population Ongoing research trials that look at possible cures and vaccines
3 Case study 35-year-old man with no past medical history is recently diagnosed with HIV after routine STI testing. What regimens do we use for him? How is this different from 20 years ago?
4 Epidemiology Prevalence (number of people living with a disease) Worldwide: 36.9 million US: 1.1 million Incidence (new cases of a disease) Worldwide: 1.8 million in 2017 US: 38,500 in 2015
5 Incidence in 2015 by transmission category CDC HIV/AIDS Statistics Center, Estimated HIV incidence and prevalence in the US
6 Populations with high incidence CDC HIV/AIDS Statistics Center, Estimated HIV incidence and prevalence in the US
7 CDC HIV/AIDS Statistics Center, Estimated HIV incidence and prevalence in the US Incidence by age, 2016
8 Classes of therapy Nucleoside and nucleotide reversetranscriptase inhibitors (NRTIs) Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) Protease inhibitors Integrase inhibitors Entry inhibition (CCR5) Monoclonal antibody
9 Mechanism Mandell, Douglas, and Bennett s Principles and Practice of Infectious Disease, 8 th edition, 2015
10 Mechanism Gandhi, M and RT Gandhi. NEJM 2014; 371:
11 Treatment principles Generally use 3 drugs At least 2 classes Usually NRTI + INSTI or PI Goal: undetectable viral load
12 NRTIs Examples of commonly used drugs/regimens Tenofovir (TDF or TAF) Viread Abacavir (ABC) Ziagen Emtricitabine (FTC) Emtriva Lamivudine (3TC) Epivir Zidovudine (AZT) Retrovir Tenofovir + emtricitabine (TDF or TAF + FTC) Truvada or Descovy
13 NNRTIs Examples of commonly used drugs/regimens continued Efavirenz (EFV) Sustiva Rilpivirine (RPV) Edurant
14 Examples of commonly used drugs/regimens continued Protease inhibitors Ritonavir (r) Norvir Lopinavir + ritonavir (LPV/r) Kaletra Atazananvir (ATV) Reyataz Darunavir (DRV) Prezista
15 Examples of commonly used drugs/regimens continued Entry Inhibitors Enfuvirtide Fuzeon Maraviroc Selzentry or Celsentri
16 Examples of commonly used drugs/regimens continued Integrase inhibitors Raltegravir (RTG) Isentress Dolutegravir (DTG) Tivicay Elvitegravir/cobicistat part of fixed dose regimens Bictegravir (BIC) part of fixed dose regimen called Biktarvy
17 First-line regimens for newly diagnosed HIV Recommended by Panel on Antiretroviral Guidelines for Adults and Adolescents BIC/TAF/FTC Biktarvy TAF/FTC + DTG Truvada or Descovy + Tivicay DTG/ABC/3TC Triumeq
18 When do we start treatment? Previously used to treat only patients with CD4 count < 500 After the START study (Strategic Timing of AntiRetroviral Treatment), paradigm shifted Decreased AIDS related events Decreased cancer rates Decreased TB rates Now we start ART for all HIV+ patients
19 Time to first primary event The INSIGHT START Study Group. NEJM 2015; 373:
20 Time to other events The INSIGHT START Study Group. NEJM 2015; 373:
21 Why do we use integrase inhibitors? Highly effective Drop viral load quickly Well-tolerated Less resistance
22 Timeline of HIV drugs 1987 FDA approves AZT 1995 HAART 1996 triple drug therapy pill regimen 2007 FDA approves first integrase inhibitor
23 How far we have come 1 pill once a day Few side effects Gets viral load to undetectable
24 Preventing HIV PrEP pre-exposure prophylaxis Truvada (only FDA approved pill) FDA approved in 2012
25 How do we use PrEP? Daily iprex study for MSM 44% reduction in incidence of HIV when on TDF/FTC Partners PrEP study in serodiscordant couples in East Africa 75% reduction in incidence of HIV on TDF/FTC TDF2 study in heterosexuals 62% effective in preventing HIV
26 iprex Grant RM, Lama JR, Anderson PL, et al; iprex Study Team. N Engl J Med 2010;363(27):
27 Partners PrEP Study Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. N Engl J Med 2012;367(5):
28 TDF-2 Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. N Engl J Med 2012;367(5):
29 How do we use PrEP? continued On-demand (not FDA approved) Take 2 pills 2-24 hours before, 3rd pill 24 hours after, 4 th pill 24 hours thereafter IPERGAY double blind RCT looking at MSM 86% reduction in HIV On average taking 15 pills a month Prevenir cohort study looking at daily vs. ondemand PrEP in MSM, ongoing 0 cases of HIV infection
30 IPERGAY Molina, JM et al for ARNS IPERGAY Study Group. N Engl J Med 2015; 373:
31 Future of PrEP Can we use Descovy (TAF/FTC)? DISCOVER trial ongoing Will know by February 2019 Will it work? (lower drug levels in tissues)
32 Trend in mortality
33 Mortality of HIV compared to other causes
34 Sexual transmission of HIV U=U undetectable = untransmissible HPTN 052 studied serodiscordant couples Early ART at enrollment led to 93% lower risk of linked partner infection No cases of HIV transmission when HIV VL was suppressed
35 HPTN 052 Cohen, MS et al for HPTN 052 Study Team. N Engl J Med 2016; 375:
36 HPTN 052 Cohen, MS et al for HPTN 052 Study Team. N Engl J Med 2016; 375:
37 Sexual transmission of HIV U=U undetectable = untransmissible PARTNER study examined condomless sexual activity in serodiscordant couples (MSM and heterosexual) 0 case of transimission over median of 2 years
38 Sexual transmission of HIV U=U undetectable = untransmissible Opposites Attract study studied serodiscordant MSM couples 0 cases of linked HIV
39 HIV and aging Patients living into their 60s and 70s with HIV Dealing with issues of aging
40 Issues affecting older HIV patients Increased risk of CV disease Osteoporosis Neuropathy Cognitive decline
41 Cardiovascular health and HIV Higher rates of MI (heart attacks) in HIV patients Why does this happen? No published evidence for prevention
42 REPRIEVE trial RCT ongoing Started March 2015 Sites include MGH Evaluating pitavastatin to reduce CVD risk in HIV+ adults Enrollment: HIV+ on ART for 6 months, with low-moderate ASCVD risk Randomized to placebo or pitavastatin
43 Can there be a cure? Antibodies ACTG trial: RC 607/ACTG A5378: A Phase I, Single- Dose Study of the Safety and Virologic Effect of an HIV-1-Specific Broadly Neutralizing Human Monoclonal Antibody, VRC-HIVMAB AB (VRC01LS) or VRC-HIVMAB AB (VRC07-523LS), Administered Intravenously to HIV-Infected Adults Aim: looking at a human monoclonal antibody that neutralizes the HIV virus Enrolling patients who are HIV+ not on ART, with VL between 500 and 100K, and CD4 >350
44 Can there be a cure? continued Vaccines Barrouch, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, doubleblind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Multicenter RCT with humans and monkeys Elicted antibody responses and T-cell response 67% protection of SHIV (HIV in monkeys) in monkeys
45 References 1. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5): Barrouch, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebocontrolled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). The Lancet vol 392, is Bavington, B et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. The Lancet vol 5, iss CDC HIV/AIDS Statistics Center, Estimated HIV incidence and prevalence in the US Clinicaltrials.gov 6. Cohen, MS et al for HPTN 052 Study Team. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016; 375: Gandhi, M and RT Gandhi. Single-Pill Combination Regimens for Treatment of HIV-1 Infection. NEJM 2014; 371: Grant RM, Lama JR, Anderson PL, et al; iprex Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27): Lundgren, JD et al for the INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. NEJM 2015; 373: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316(2): doi: /jama Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367(5): Molina, JM et al for ARNS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 2015; 373: Tsibris, Athe and Martin Hirsch. Antiretroviral Therapy for HIV infection, Mandell, Douglas, and Bennett s Principles and Practice of Infectious Disease, 8 th edition, 2015.
HIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
ART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
Nothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
HIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
Simplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
treatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
HIV Clinical Nurse Specialist CCDHB Wellington
RN James Rice-Davies HIV Clinical Nurse Specialist CCDHB Wellington 11:00-11:55 WS #88: Undiagnosed HIV in Your Practice 12:05-13:00 WS #99: Undiagnosed HIV in Your Practice (Repeated) HIV- Undiagnosed
Exploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV
PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV Laura Beauchamps, MD Assistant Professor Division of Infectious Diseases University of Mississippi Medical Center Principal Investigator
COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
Biomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
Nobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
Sculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
Selecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
Didactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
Jonathan Cohn MD Wayne State University July 24,
Jonathan Cohn MD Wayne State University July 24, 2017 www.matecmichigan.org jcohn@med.wayne.edu Current HIV Test Sequence 4 th Generation Ag/Ab Combo > Differentiation Assay Abbott Architect Alere Determine
Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
Comprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
PrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
HIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
Principles of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
Susan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
ANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
HIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
Approach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
Starting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
New Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
HIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
Overview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
HIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
Objectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
Matters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
Criteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER. HIV and Oral Health in the Era of Antiretroviral Therapy
SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER HIV and Oral Health in the Era of Antiretroviral Therapy SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER Mark Schweizer, DDS MPH Director of Development
HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
Midwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
Susan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
Dr Valérie Martinez-Pourcher
Educa&ng Nurses About An&retrovirals and HIV Preven&on - State of the Science, Uptake Challenges, and Barriers Dr Valérie Martinez-Pourcher Pitié-Salpêtrière Hospital Paris We need to control HIV replication
What's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
Using anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
The ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination
Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement
Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
HIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract. Sandrine LEFEUVRE, Julie BOIS-MAUBLANC, Camélia GUBAVU,
A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
Joseph Cofrancesco Jr, MD, MPH, FACP
Friday Case Series Joseph Cofrancesco Jr, MD, MPH, FACP Associate Professor of Medicine Director and Johns Hopkins Institute for Excellence in Education Professor of Medicine Join us on Facebook Follow
10/8/18 LAURA KOGELMAN, MD. Play Bumper Video. Associate Professor of Medicine. Director, Infectious Diseases Clinic. Boston, Massachusetts
LAURA KOGELMAN, MD Associate Professor of Medicine Tufts University School of Medicine Director, Infectious Diseases Clinic Tufts Medical Center Boston, Massachusetts Play Bumper Video 1 Disclosures All
HIV Clinical Update- HIV prevention
HIV Clinical Update- HIV prevention 18 th Australian and New Zealand Conference on Haemophilia and Rare Bleeding Disorders, Melbourne October 13 th 2017 Edwina Wright Disclosures None in the past 12 months
PEP, PREP, HPTN052 and MLN2238
PEP, PREP, HPTN052 and MLN2238 Understanding the alphabet soup of HIV prevention and cure strategies Christina G Rivera, PharmD, BCPS Pharmacy Grand Rounds August 15, 2017 2017 MFMER slide-1 Presentation
SA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
Starting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation November
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
Starting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
The Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
The role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p5 p6 p7 HIV CARE NEWS New drugs: dolutegravir, MK-1439, cenicriviroc, and HIV and heart health. HIV PrEP NEWS Disappointing
HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients
The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients John T. Carlo, MD, MS Chief Executive Officer AIDS ARMS, INC. https://twitter.com/jtcarlo Conflict of Interest None 2 Learning Objectives
HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
HIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
Fundamentals of Antiretroviral Therapy
Fundamentals of Antiretroviral Therapy Southeast AIDS Education & Training Center HIV Clinical Overview 12 May 2016 Todd Hulgan, MD, MPH Department of Medicine, Division of Infectious Diseases Vanderbilt
Faculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
HIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
HIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
Addressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
ART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
PrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
Management of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
NULOESIDE/TIDE REVERSE TRANSRIPTASE INHIBITORS (N(t)RTIs) Abacavir AB (Ziagen) Emtricitabine FT (Emtriva) Lamivudine 3T (Epivir) Tenofovir disoproxil fumarate TDF (Viread) Zidovudine AZT, ZDV (Retrovir)
The next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state